 |
     |
   |
|
 |
|
|
 Bringing a Biopharmaceutical Company Across the Border Helix BioPharma Corp. is an emerging Canadian company developing innovative medicines primarily in the areas of cancer prevention and treatment. With products in development for therapies for cervical cancer and lung cancer, Helix wanted to expand its investor following beyond Canada and Europe as well as position its technology and products for business development opportunities. With Russo Partners on board, Helix focused on fine-tuning its messaging and positioning, launching a proactive news bureau with a U.S. emphasis and building relationships with members of the U.S. media and investment communities alike. Within the first 60 days of the PR program launch, Helix had completed a full slate of meetings that produced company profiles, inclusion in industry round-up articles and invitations to participate in major investor conferences. The significant results did what they were supposed to: attracted the attention of the company’s target audiences in the U.S. |
|
|
|
© 2009 Russo Partners
|
site design and programming by bfwinteractive |